Haemonetics
197 hedge funds and large institutions have $2.19B invested in Haemonetics in 2017 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 89 increasing their positions, 50 reducing their positions, and 17 closing their positions.
94% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 17
78% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 50
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
50% more call options, than puts
Call options by funds: $6K | Put options by funds: $4K
9% more funds holding
Funds holding: 181 → 197 (+16)
0.59% more ownership
Funds ownership: 105.07% → 105.66% (+0.59%)
1% less capital invested
Capital invested by funds: $2.22B → $2.19B (-$26.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
+$14.5M |
| 2 |
HM
HealthCor Management
New York
|
+$10.5M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$9.79M |
| 4 |
Morgan Stanley
New York
|
+$9.48M |
| 5 |
ACA
Anchor Capital Advisors
Boston,
Massachusetts
|
+$9.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
-$19.2M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$14.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.91M |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$9.23M |
| 5 |
Millennium Management
New York
|
-$8.45M |
HAE Hedge Fund Activity: Q2 2017 in Review
197 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q2 2017, worth a combined $2.19B — down 1.2% from $2.22B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new HAE positions and 17 closed out — a net gain of 16 holders — while 89 added to existing stakes and 50 trimmed.
The largest buyer was Norges Bank, adding an estimated $14.5M. The largest seller was Polar Capital, exiting entirely with an estimated $19.2M sold.
- 197 institutional investors held Haemonetics (HAE) as of Q2 2017, up from 181 in Q1 2017.
- Funds reported $2.19B of Haemonetics stock for Q2 2017, down 1.2% quarter-over-quarter.
- 33 funds opened new Haemonetics positions in Q2 2017 and 17 closed out, a net change of +16 holders.
- The largest Haemonetics buyer in Q2 2017 was Norges Bank, an estimated $14.5M added.
- The largest Haemonetics seller in Q2 2017 was Polar Capital, an estimated $19.2M sold.
Based on aggregated 13F filings for Q2 2017.